Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(23 sites)

China

The First Affiliated Hospital of Anhui Medical College, Hefei, Anhui

The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Hefei, Anhui

Beijing Hospital, Beijing, Beijing Municipality

Peking University People's Hospital, Beijing, Beijing Municipality

Peking University Third Hospital, Beijing, Beijing Municipality

First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong

Guangdong Provincial People's Hospital, Guangzhou, Guangdong

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Wuhan Union Hospital, China, Wuhan, Hubei

Second Xiangya Hospital of Central South University, Changsha, Hunan

Xiangya Hospital of Central South University, Changsha, Hunan

The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia

First Hospital of China Medical University, Shenyang, Liaoning

Shandong Provincial Hospital, Jinan, Shandong

Changhai Hospital, Shanghai, Shanghai Municipality

RenJi Hospital, Shanghai, Shanghai Municipality

Shanxi Bethune Hospital, Taiyuan, Shanxi

West China Hospital, Chengdu, Sichuan

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality

Tianjin First Central Hospital, Tianjin, Tianjin Municipality

Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality

People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, Xinjiang Uygur Autonomous Region

The First People's Hospital of Yunnan, Kunming, Yunnan